Citi raised the firm’s price target on Royalty Pharma (RPRX) to $50 from $48 and keeps a Buy rating on the shares. The firm adjusted targets in the biopharma group as part of a Q4 preview. Estimates that are “beatable” and lower policy risk should create a favorable setup in 2026 for the group, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma provides update on business performance
- Royalty Pharma, Teva enter agreement to accelerate development of TEV-‘408
- Royalty Pharma board increases quarterly dividend 6.8% to 23.5c per share
- Royalty Pharma acquires reaming royalty interest in Evrysdi for $240M upfront
- Royalty Pharma Announces Planned Legal Leadership Transition